Truveta Data

Regulatory-grade EHR data, linked with claims and SDOH, enabling research across all diseases, drugs, and devices

Improving patient outcomes has been hindered by fragmented, incomplete, and inaccessible patient data – until now

Truveta Data comes from a growing collective of more than 30 health systems that provide more than 18% of daily clinical care across the country, representing the full diversity of the US 

100M+

patients and growing

5B+

clinical notes

150K+

unique medical devices

5+

years patient history

440+

SDOH attributes

Explore complete and research-ready patient-level data

EHR data is linked with claims, SDOH, and mortality data for a complete view into the patient journey

Stringent data quality standards are met across all data elements, including:

Clinical notes (disease staging, family history, symptoms, interpretations of findings, clinical recommendations)
Lab tests and results
Biometric data
Imaging study results
Genomic biomarkers
Device data (at UDI level)
Immunizations
Care settings
Biopsy reports
Medication dosage data
Pharmacy fill data
Diagnosis and procedure data
And more

The clinical depth in Truveta Data supports populations with highly specific I/E criteria for any disease, drug, or device

Diagram detailing inclusion and exclusion criteria applied to a heart failure population in Truveta Data. The criteria encompass medication use, length of stay, outpatient encounters, laboratory results, comorbidities, and device use. The visual representation offers a comprehensive overview of the selection criteria, aiding in understanding the parameters used to define the study population.

Case study

Comparing the safety of novel pulmonary embolism devices

Real-world data is essential for filling knowledge gaps on drugs and devices. To assess the real-world safety of its EKOS device versus a competitor device, Boston Scientific enlisted independent researchers to compare major bleeding event risks using Truveta Data.

Case study

Comparing the safety of novel pulmonary embolism devices

Real-world data is essential for filling knowledge gaps on drugs and devices. To assess the real-world safety of its EKOS device versus a competitor device, Boston Scientific enlisted independent researchers to compare major bleeding event risks using Truveta Data.

Unprecedented access to notes and images

Unlock meaningful insights within clinical notes

Uncover previously hidden, deep clinical insights from more than 5 billion free-text notes with an average of 75 clinical notes per patient.

Progress notes, discharge reports, lab reports, and transcribed telephone encounters reveal details like disease symptoms, clinical status measures or scores, and reasons for medication changes.

L

Stage of illness

L

Treatment, reason for change in treatment regimen

L

Treatment not considered due to patient preference

L

Genomic variants

L

Specific staging information across recurrence staging, clinical staging, and pathology staging

Learn from medical images

Gain access to full images, including MRI’s, CT scans, X-rays, ultrasounds and digital pathology to study digital images alongside the complete, longitudinal patient record to better understand diagnosis, treatment, and prognosis.

Learn from medical images

Gain access to full images, including MRI’s, CT scans, X-rays, ultrasounds and digital pathology to study digital images alongside the complete, longitudinal patient record to better understand diagnosis, treatment, and prognosis.

Daily updated data cleaned with clinical expert-led AI

Billions of data points cleaned with unmatched accuracy

Truveta Language Model, a large-language, multi-modal AI model, transforms billions of data points with industry-leading normalization. Data is carefully de-identified with the highest standards of security and privacy protection.

“We are thrilled to partner with Truveta to use their unprecedented access to EHR data for real-world data research and advance our understanding of epilepsy and seizure disorders. Through Truveta, we can uncover insights into patient care and outcomes that we’ve never seen before at this scale and breadth of data, including seizure frequency in clinical notes. Together, we believe we can drive meaningful improvements in the lives of patients living with epilepsy.”

Sean Stern

Director Health Economics Outcomes Research (HEOR), SK Life Science Inc.

Explore whitepapers

Truveta Language Model

Data quality

Data security

Patient privacy

Every Truveta study can be a health equity study

Truveta Data is linked with SDOH data from LexisNexis Risk Solutions including 440+ attributes on education, income, housing stability, social support, and moreÂ